| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Review |
| Article Title |
Serum biomarkers in diabetic kidney disease: A comprehensive narrative review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Guido Gembillo, Luca Soraci, Giuseppe Spadaro, Rossella Messina, Felicia Cuzzola, Michela Calderone, Maria Federica Ricca, Simona Di Piazza, Flavia Sudano, Maria Elsa Gambuzza, Maria Princiotto, Lorenzo Lo Cicero and Domenico Santoro |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guido Gembillo, Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 1, Messina 98125, Sicilia, Italy. guidogembillo@live.it |
| Key Words |
Diabetic nephropathy; Chronic kidney disease; Albuminuria; Renal function; Inflammation markers; Diabetes; Biomarkers |
| Core Tip |
Diabetic kidney disease is the main cause of end-stage renal disease, yet early detection is limited by the poor sensitivity of serum creatinine and estimated glomerular filtration rate. Novel biomarkers such as cystatin C, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and tumor necrosis factor receptors show superior accuracy for identifying early damage and predicting progression. Emerging markers, including adropin, soluble urokinase plasminogen activator receptor, monocyte chemoattractant protein-1, chitinase-3-like protein 1, endostatin, zinc-α2-glycoprotein, PromarkerD, and microRNAs, provide additional value for risk stratification and personalized therapy. Integration of validated multi-marker panels may transform monitoring and management, improving outcomes for patients with diabetes. |
| Publish Date |
2026-04-14 08:58 |
| Citation |
Gembillo G, Soraci L, Spadaro G, Messina R, Cuzzola F, Calderone M, Ricca MF, Di Piazza S, Sudano F, Gambuzza ME, Princiotto M, Lo Cicero L, Santoro D. Serum biomarkers in diabetic kidney disease: A comprehensive narrative review. World J Diabetes 2026; 17(4): 113748 |
| URL |
https://www.wjgnet.com/1948-9358/full/v17/i4/113748.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v17.i4.113748 |
